Trilaciclib for the prevention reduction of chemotherapy-induced myelosuppression in the management of extensive-stage small cell lung cancer: a profile of its use

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest ES Kim, a contracted employee of Adis International Ltd/Springer Nature, and SJ Keam, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability not applicable.

Additional information about this Adis Drug Review can be found here.

Trilaciclib (COSELA™) is a transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is approved in the USA to decrease the incidence of chemotherapy-induced myelosuppression (CIM) when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen in adults being treated for extensive-stage small cell lung cancer (ES-SCLC). It is the first approved therapy to provide myeloprotection, and when administered before chemotherapy, it is a valuable option for decreasing the incidence of CIM. In three clinical randomized trials, trilaciclib administration prior to standard-of-care chemotherapy for ES-SCLC reduced myelosuppression and the need for rescue interventions, improved patient-reported outcomes and the safety profile of the chemotherapy regimens, and had no impact on antitumor efficacy.

© Springer Nature Switzerland AG 2022